Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

Lara C. Pullen, PhD  |  February 18, 2019

CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…

Filed under:Drug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingGuidelinesHydroxychloroquine (HCQ)

Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Carina Stanton  |  February 14, 2019

At diagnosis, temporal artery biopsy results and large-vessel involvement of patients with giant cell arteritis may be stronger predictors of mortality than cardiovascular risk factors…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)mortality

Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation

Thomas R. Collins  |  January 17, 2019

CHICAGO—With an ever-strengthening foundation beneath the pathophysiology and prediction of rheumatoid arthritis (RA), the field may soon focus more intently on prevention, an expert said at the 2018 ACR/ARHP Annual Meeting. The session also covered the latest in remission targets and therapy de-escalation. RA Prevention Kevin Deane, MD, PhD, associate professor of medicine and principal…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingpreventionRemissiontreatment de-escalation

The ACR Has Introduced a New Reproductive Health Guideline Draft

Susan Bernstein  |  January 17, 2019

CHICAGO—Reproductive health can be a concern for patients with rheumatic diseases, and practitioners in both disciplines often work closely together. The Reproductive Health in Rheumatic and Musculoskeletal Diseases Guideline, a draft of new clinical recommendations developed by an ACR-convened group for pregnant women, post-menopausal women, lactating women, and women and men trying to conceive or…

Filed under:Clinical Criteria/GuidelinesMeeting Reports Tagged with:deficiency of adenosine deaminase 2 (DADA2)Dr. Chip Chamberspolyarteritis nodosa

Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

Susan Bernstein  |  December 18, 2018

Varicella-zoster-virus (VZV) reactivation, which can cause patients to develop herpes zoster (i.e., shingles), occurs more frequently in patients with systemic vasculitis and systemic lupus erythematosus (SLE) who have received intravenous cyclophosphamide than in otherwise healthy adults, according to a retrospective study published in The Journal of Rheumatology by researchers in France.1 The study also shows…

Filed under:ConditionsResearch RheumSystemic Lupus ErythematosusVasculitis Tagged with:cyclophosphamideherpes zostershinglesvalacyclovir

Do Not Get Us Started on Acthar

Do Not Get Us Started on Acthar

Megan Elizabeth Bowles Clowse, MD, MPH & David Leverenz, MD  |  December 17, 2018

As rheumatologists, we have a love-hate relationship with the corticosteroid prednisone, a feeling many of our patients share. It’s our most effective medication to quickly shut down an overactive immune system. When we have a patient with life- or organ-threatening autoimmune disease—severe lupus affecting the kidneys or vasculitis causing hemorrhage in the lungs, for example—large…

Filed under:OpinionSpeak Out Rheum Tagged with:Actharadrenocorticotropic hormoneCorticosteroidsDrug UpdatesOpinionprednisone

Can Integrated Care Lead to Better Outcomes?

Can Integrated Care Lead to Better Outcomes?

Shikha Mittoo, MD, MHS, FRCPC  |  December 17, 2018

A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…

Filed under:Conditions Tagged with:Association of Rheumatology Professionals (ARP)Integrated Careinterdisciplinarymultidisciplinary care

Pediatric Lupus Outcomes: Researchers Follow Kids into Adulthood

Linda Childers  |  November 19, 2018

A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:FlaresSLICC/ACR Damage Index

Complications to Watch for in Pregnant Rheumatology Patients

Anat Chemerinski, MD, & Jason Liebowitz, MD  |  November 18, 2018

BALTIMORE—Understanding issues regarding pregnancy in women with rheumatic disease is important to patients and physicians alike, said Bonnie Bermas, MD, the Dr. Morris Ziff Distinguished Professor in Rheumatology at UT Southwestern Medical Center, Dallas, in her recent lecture at the Maryland Society for the Rheumatic Diseases.The physiologic changes in normal pregnancy, which include increased circulating…

Filed under:ConditionsMeeting Reports Tagged with:pregnancy

Ustekinumab May Be Effective for Lupus

Lara C. Pullen, PhD  |  November 12, 2018

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupussystemic lupus erythematosus (SLE)ustekinumab

  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences